The effect of maslinic acid on cognitive dysfunction induced by cholinergic blockade in mice. (1st April 2020)

• Record Type: Journal Article
• Authors: Bae, Ho Jung; Kim, Jihyun; Kim, Jaehoon; Goo, Nayeon; Cai, Mudan; Cho, Kyungnam; Jung, Seo Yun; Kwon, Huiyoung; Kim, Dong Hyun; Jang, Dae Sik; Ryu, Jong Hoon
• Is Part Of: British journal of pharmacology. Volume 177:Number 14(2020)
• Page Start: 3197
• Page End: 3209
• Publication Date: 2020-04-01
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15042
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: Alzheimer's disease (AD) is the most prevalent disease associated with cognitive dysfunction. Current AD therapeutic agents have several gastrointestinal or psychological adverse effects and therefore, novel therapeutic agents with fewer adverse effects must be developed. Previously, we demonstrated that oleanolic acid, which is similar in chemical structure to maslinic acid, ameliorates cognitive impairment through the activation of tropomyosin receptor kinase (TrkB)–ERK–cAMP response element‐binding protein (CREB) phosphorylation and increased levels of brain‐derived neurotrophic factor (BDNF). In the present study, we investigate the effect of maslinic acid on cholinergic blockade‐induced memory impairment in mice. Methods and Key Results: Maslinic acid reversed scopolamine‐induced memory impairment, as determined by the Y‐maze, passive avoidance and Morris water maze tests. In addition, we also observed that ERK–CREB, PI3K and PKB (Akt) phosphorylation levels were increased by maslinic acid administration in the mouse hippocampus. Moreover, we determined that the effects of maslinic acid on scopolamine‐induced memory impairment in the passive avoidance test were abolished by a specific TrkB receptor antagonist (ANA‐12). Additionally, we observed similar temporal changes in the expression levels between BDNF and tissue plasminogen activator in the hippocampus. Conclusion and Implications: These findings suggest that maslinic acid enhances cognitive function through the activation of BDNF and its downstream pathway signalling in the hippocampus and that it might be a potential therapeutic agent for cognitive decline, such as that observed in AD.